Patents Assigned to ISIS Pharmaceuticals Inc.
  • Antisense modulation of PTP1B expression
    Patent number: 8658783
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: February 25, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Susan M. Freier
  • Modulation of angiopoietin-like 3 expression
    Patent number: 8653047
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: February 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee
  • 2-aminopyridine and 2-pyridone C-nucleosides
    Patent number: 8653248
    Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: February 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
  • Modulation of Hepatitis B virus (HBV) expression
    Patent number: 8642752
    Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Michael L. McCaleb, Hong Zhang
  • Modulation of glucagon receptor expression
    Patent number: 8642753
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie, Robert McKay, Sanjay Bhanot
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8637484
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: January 28, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • Compounds and methods for modulating protein expression
    Patent number: 8637478
    Abstract: The present invention provides compounds and methods for modulating expression of a protein, including, but not limited to, modulating splicing of a pre-mRNA to modulate the amount of one or more variants of a protein.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: January 28, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: C. Frank Bennett
  • COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
    Publication number: 20140011860
    Abstract: Compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells are provided. The compounds and methods modulate target nucleic acids in a sub-nuclear organelle include, but are not limited to, the nucleolus and/or a cajal body of animal cells.
    Type: Application
    Filed: July 19, 2011
    Publication date: January 9, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Xue-hai Liang, Stanley T. Crooke
  • Antisense oligonucleotide modulation of STAT3 expression
    Patent number: 8623643
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: January 7, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: James G. Karras
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8623836
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: January 7, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • MODULATION OF ALPHA SYNUCLEIN EXPRESSION
    Publication number: 20140005252
    Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
    Type: Application
    Filed: November 17, 2011
    Publication date: January 2, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Jyothi Mallajosyula
  • Modulation of exportin 5 expression
    Patent number: 8614310
    Abstract: Compounds, compositions and methods are provided for modulating the expression of exportin 5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding exportin 5. Methods of using these compounds for modulation of exportin 5 expression and for diagnosis and treatment of diseases and conditions associated with expression of exportin 5 are provided.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: December 24, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Kenneth W. Dobie
  • ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION
    Publication number: 20130331435
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 12, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • METHODS FOR MODULATING FACTOR 12 EXPRESSION
    Publication number: 20130331434
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: November 8, 2011
    Publication date: December 12, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Robert A. MacLeod, Jeffrey R. Crosby
  • Compositions comprising alternating 2?-modified nucleosides for use in gene modulation
    Patent number: 8604183
    Abstract: The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: December 10, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Charles Allerson, Balkrishen Bhat, Anne B. Eldrup, Muthiah Manoharan, Richard H. Griffey, Brenda F. Baker, Eric E. Swayze
  • Cyclohexenyl nucleic acids analogs
    Patent number: 8604192
    Abstract: The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclo-hexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: December 10, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze
  • 5'-END DERIVATIVES
    Publication number: 20130323836
    Abstract: The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Application
    Filed: April 22, 2011
    Publication date: December 5, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Ivan Zlatev, Eric E. Swayze, Thazha P. Prakash, Walter F. Lima
  • MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
    Publication number: 20130317085
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III.
    Type: Application
    Filed: August 7, 2013
    Publication date: November 28, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Compounds and methods for modulating expression of PTP1B
    Patent number: 8586554
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: November 19, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Modulation of forkhead box O1A expression
    Patent number: 8580948
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: November 12, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Robert McKay, Sanjay K. Pandey